cholorambucil versus cholorambucil plus prednisolone as first-line therapy of chronic lymphocytic leukemia in west of iran
نویسندگان
چکیده
1. dept. of hematology and medical oncology, kermanshah university of medical sciences, kermanshah, iran 2. students research committee, kermanshah university of medical sciences, kermanshah, iran 3. medical biology research center, kermanshah university of medical sciences, kermanshah, iran corresponding author: masoud sadeghi, msc. tel: (+98) 9185960644 email: [email protected] received: 03 aug. 2014 accepted: 07 feb. 2015 iran j cancer prev. 2015; 2:94-9. abstract background: chronic lymphocytic leukemia (cll) has been the most common type of leukemia in adults worldwide, and then more common in the elderly, markedly more common in patients over the age of 65 years. methods: seventy patients with cll have referred to clinic of hematology-oncology, kermanshah, iran, between jan 2000 and jun 2014. we have analyzed age, sex, survival, kind of chemotherapy and type of response in all of the patients with chronic lymphocytic leukemia. survival curves of complete response patients have compared with partial response, by log-rank test using the prism 5 graphpad software for the five-year period with two years follow up. results: the mean age of patients was 61.57±8.88 years that 55.7% were males. between the 70 patients, 40 patients (57.1%) have started treatment with chlorambucil and 30 patients (42.9%) with chlorambucil plus prednisolone. among the forty patients that have treated with chlorambucil, overall response rate was 95% that 9 patients (22.5%) had complete response . among the 30 patients that have treated with chlorambucil plus prednisolone, overall response rate was 96%, that 9 patients (30%) had complete response after six months of treatment. the mean of five-year overall survival for treated patients with chlorambucil and chlorambucil plus prednisolone in the first-line of therapy was 38.5 and 40.5 months, respectively. conclusion: combination of prednisolon to chlorambucil has increased survival rate in the patients more than mono-therapy with chlorambucil and also the complete response rate to chlorambucil in west of iran was better than other areas of world.
منابع مشابه
Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran
BACKGROUND Chronic lymphocytic leukemia (CLL) has been the most common type of leukemia in adults worldwide, and then more common in the elderly, markedly more common in patients over the age of 65 years. METHODS Seventy patients with CLL have referred to Clinic of Hematology-Oncology, Kermanshah, Iran, between Jan 2000 and Jun 2014. We have analyzed age, sex, survival, kind of chemotherapy a...
متن کاملChronic lymphocytic leukemia (CLL): first-line treatment.
For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is...
متن کاملCost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada.
Table 1. Drug Acquisition, Administration, and Monitoring Costs for FirstLine Treatment With OChl and Chl Cost Type OChl Chl Drug acquisition Ofatumumab, 100 mg vial $336 – Chlorambucil, 25 x 2 mg pack $35 $35 Administration Induction infusion in first cycle (O) $1,039 – Regular infusion in subsequent cycles (O) $818 – Oral chemotherapy dispensing (Chl)a $9 $9 Monitoring (per chemo cycle)b $119...
متن کاملFront-line therapy for chronic lymphocytic leukemia.
BACKGROUND Historically, alkylator-based therapy has been used to treat patients with chronic lymphocytic leukemia (CLL). More effective therapies, such as the use of monoclonal antibodies in combination with chemotherapy, have been shown to prolong both progression-free survival and overall survival. Improvements in the identification of prognostic markers for CLL, as well as novel combination...
متن کاملFirst-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not s...
متن کاملThe role of microRNA in acute/chronic, myeloid/lymphocytic leukemia
MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of cancer preventionجلد ۸، شماره ۲، صفحات ۹۴-۹۹
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023